Clinical-grade CAR-T cell manufacturing was performed in a closed system using a second-generation CD19 vector with 41BB costimulatory domain. Quality control was assessed at different points in the ...

“CLN-978 is the only CD19-targeting T cell engager advancing a global regulatory development plan that includes a US FDA-cleared IND. Delivering the potency of T cell redirecting therapy with the ...